Skip to main content
. 2019 Feb 15;12:689–700. doi: 10.2147/JPR.S188675

Table 1.

Demographic and baseline characteristics (modified intention-to-treat population)

Variable Statistic Methoxyflurane (n=47) Placebo (n=48) Total (N=95)

Age (years) n 47 48 95
Mean (SD) 14.4 (1.4) 13.5 (1.5) 14 (1.5)
Median (range) 14 (12–17) 13 (12–17) 14 (12–17)
Gender, n (%) Male 32 (68.1) 35 (72.9) 67 (70.5)
Female 15 (31.9) 13 (27.1) 28 (29.5)
Race, n (%) White 41 (87.2) 40 (83.3) 81 (85.3)
Asian 0 5 (10.4) 5 (5.3)
Black 1 (2.1) 1 (2.1) 2 (2.1)
Other 5 (10.6) 2 (4.2) 7 (7.4)
Injury type, n (%) (first injurya) Other 24 (51.1) 29 (60.4) 53 (55.8)
Fracture 11 (23.4) 11 (22.9) 22 (23.2)
Contusion 9 (19.1) 6 (12.5) 15 (15.8)
Dislocation 1 (2.1) 1 (2.1) 2 (2.1)
Laceration 1 (2.1) 1 (2.1) 2 (2.1)
Injury due to foreign body 1 (2.1) 0 1 (1.1)
Site, n (%) Right upper limb 13 (27.7) 14 (29.2) 27 (28.4)
Left upper limb 13 (27.7) 8 (16.7) 21 (22.1)
Right lower limb 6 (12.8) 11 (22.9) 17 (17.9)
Left lower limb 5 (10.6) 9 (18.8) 14 (14.7)
Other 7 (14.9) 4 (8.3) 11 (11.6)
Face 2 (4.3) 1 (2.1) 3 (3.2)
Back 1 (2.1) 1 (2.1) 2 (2.1)
VAS pain intensity (mm) 45 47
Mean (SD) 61.7 (16.56) 61.0 (13.33)
Median (range) 64 (23–100) 58 (35–87)

Notes:

a

One patient had >1 injury (second and third injuries were contusion and abrasion to knee and finger). “–” indicates data not available.

Abbreviation: VAS, visual analog scale.